Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.26
RHHBY's Cash to Debt is ranked lower than
92% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. RHHBY: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
RHHBY' s Cash to Debt Range Over the Past 10 Years
Min: 0.26  Med: 0.64 Max: N/A
Current: 0.26
Equity to Asset 0.25
RHHBY's Equity to Asset is ranked lower than
85% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RHHBY: 0.25 )
Ranked among companies with meaningful Equity to Asset only.
RHHBY' s Equity to Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.25 Max: 0.59
Current: 0.25
0.09
0.59
Interest Coverage 18.21
RHHBY's Interest Coverage is ranked lower than
81% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RHHBY: 18.21 )
Ranked among companies with meaningful Interest Coverage only.
RHHBY' s Interest Coverage Range Over the Past 10 Years
Min: 5.94  Med: 12.43 Max: N/A
Current: 18.21
F-Score: 5
Z-Score: 3.40
M-Score: -2.86
WACC vs ROIC
6.30%
28.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 27.49
RHHBY's Operating margin (%) is ranked higher than
91% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. RHHBY: 27.49 )
Ranked among companies with meaningful Operating margin (%) only.
RHHBY' s Operating margin (%) Range Over the Past 10 Years
Min: 25.03  Med: 28.74 Max: 33.69
Current: 27.49
25.03
33.69
Net-margin (%) 17.53
RHHBY's Net-margin (%) is ranked higher than
88% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. RHHBY: 17.53 )
Ranked among companies with meaningful Net-margin (%) only.
RHHBY' s Net-margin (%) Range Over the Past 10 Years
Min: 15.87  Med: 18.73 Max: 22.97
Current: 17.53
15.87
22.97
ROE (%) 48.21
RHHBY's ROE (%) is ranked higher than
97% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. RHHBY: 48.21 )
Ranked among companies with meaningful ROE (%) only.
RHHBY' s ROE (%) Range Over the Past 10 Years
Min: 19.94  Med: 45.85 Max: 102.95
Current: 48.21
19.94
102.95
ROA (%) 12.44
RHHBY's ROA (%) is ranked higher than
92% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. RHHBY: 12.44 )
Ranked among companies with meaningful ROA (%) only.
RHHBY' s ROA (%) Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 12.44
10.33
17.58
ROC (Joel Greenblatt) (%) 62.92
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. RHHBY: 62.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RHHBY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 52.39  Med: 64.09 Max: 84.52
Current: 62.92
52.39
84.52
Revenue Growth (3Y)(%) 3.20
RHHBY's Revenue Growth (3Y)(%) is ranked lower than
52% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. RHHBY: 3.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RHHBY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.5  Med: 5.4 Max: 394
Current: 3.2
-3.5
394
EBITDA Growth (3Y)(%) -0.40
RHHBY's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. RHHBY: -0.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RHHBY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2  Med: 13.1 Max: 271.3
Current: -0.4
-2
271.3
EPS Growth (3Y)(%) -2.30
RHHBY's EPS Growth (3Y)(%) is ranked higher than
52% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. RHHBY: -2.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RHHBY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.2  Med: 6.9 Max: 340.9
Current: -2.3
-3.2
340.9
» RHHBY's 10-Y Financials

Financials (Next Earnings Date: 2017-02-01)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

RHHBY Guru Trades in Q4 2015

Ken Fisher 14,630,453 sh (+0.63%)
Mairs and Power 2,714,500 sh (+0.06%)
» More
Q1 2016

RHHBY Guru Trades in Q1 2016

Ken Fisher 14,906,191 sh (+1.88%)
Mairs and Power 2,723,637 sh (+0.34%)
» More
Q2 2016

RHHBY Guru Trades in Q2 2016

Mairs and Power 4,005,602 sh (+47.07%)
Ken Fisher 15,142,209 sh (+1.58%)
» More
Q3 2016

RHHBY Guru Trades in Q3 2016

Mairs and Power 4,644,431 sh (+15.95%)
Ken Fisher 15,126,928 sh (-0.10%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AMGN, NAS:GILD, NAS:CELG, OTCPK:NONOF, NAS:BIIB, OTCPK:SHPGF, NAS:REGN, OTCPK:CSLLY, NAS:ALXN, NAS:VRTX, NAS:INCY, OTCPK:ALIOY, NAS:BMRN, OTCPK:GIKLY, NAS:MDVN, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMF, NAS:SGEN, NAS:ALKS » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience. It has more than 66 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals and Chugai, whereas Genentech as the former third segment has been integrated into Roche Pharmaceuticals. The Diagnostics Division consists of the following four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Top Ranked Articles about Roche Holding AG

Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee Therapy is used to treat chronic lymphocytic leukaemia
Today Roche (RHHBY) reported a positive opinion concerning Venclyxt (venetoclax) from the European Union Committee for Medicinal Products for Human Use (CHMP). Read more...
Innovative Diagnostic and Therapeutic Products Seen at Roche Roche is arguably the strongest company in the biotech field​
In the world of biotechnology and pharmaceuticals, arguably the largest in the field is the company known as Roche (RHHBY). Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver great benefits to patients and healthcare professionals, from early detection and prevention of disease to treatment and treatment monitoring. Read more...
Does Biotech’s Recent Bounce Have Legs? Examining 3 Big Pharma stocks that dominate the making of cancer-fighting treatments
The beleaguered biotechology sector, which has endured political controversy amid charges of price gouging, is now on an upward trajectory. The Nasdaq Biotechnology Index, after falling 17.46% year to date, has jumped 9.04% over the past month. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.88
RHHBY's P/E(ttm) is ranked higher than
61% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. RHHBY: 21.88 )
Ranked among companies with meaningful P/E(ttm) only.
RHHBY' s P/E(ttm) Range Over the Past 10 Years
Min: 13.05  Med: 19.99 Max: 36.39
Current: 21.88
13.05
36.39
Forward P/E 13.25
RHHBY's Forward P/E is ranked higher than
60% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. RHHBY: 13.25 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.88
RHHBY's PE(NRI) is ranked higher than
62% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. RHHBY: 21.88 )
Ranked among companies with meaningful PE(NRI) only.
RHHBY' s PE(NRI) Range Over the Past 10 Years
Min: 13.05  Med: 19.99 Max: 36.23
Current: 21.88
13.05
36.23
Price/Owner Earnings (ttm) 15.82
RHHBY's Price/Owner Earnings (ttm) is ranked higher than
71% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. RHHBY: 15.82 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RHHBY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.58  Med: 15.45 Max: 24.1
Current: 15.82
9.58
24.1
P/B 10.60
RHHBY's P/B is ranked lower than
86% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. RHHBY: 10.60 )
Ranked among companies with meaningful P/B only.
RHHBY' s P/B Range Over the Past 10 Years
Min: 2.64  Med: 11.17 Max: 22.21
Current: 10.6
2.64
22.21
P/S 3.93
RHHBY's P/S is ranked higher than
75% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. RHHBY: 3.93 )
Ranked among companies with meaningful P/S only.
RHHBY' s P/S Range Over the Past 10 Years
Min: 2.38  Med: 4.09 Max: 6.05
Current: 3.93
2.38
6.05
PFCF 17.84
RHHBY's PFCF is ranked higher than
63% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. RHHBY: 17.84 )
Ranked among companies with meaningful PFCF only.
RHHBY' s PFCF Range Over the Past 10 Years
Min: 8.6  Med: 17.44 Max: 37.16
Current: 17.84
8.6
37.16
POCF 13.02
RHHBY's POCF is ranked higher than
71% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. RHHBY: 13.02 )
Ranked among companies with meaningful POCF only.
RHHBY' s POCF Range Over the Past 10 Years
Min: 6.98  Med: 13.68 Max: 22.22
Current: 13.02
6.98
22.22
EV-to-EBIT 16.88
RHHBY's EV-to-EBIT is ranked higher than
55% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. RHHBY: 16.88 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHBY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.6  Med: 14.2 Max: 22.3
Current: 16.88
7.6
22.3
EV-to-EBITDA 13.16
RHHBY's EV-to-EBITDA is ranked higher than
59% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. RHHBY: 13.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHBY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 12.1 Max: 17.9
Current: 13.16
6.4
17.9
PEG 18.33
RHHBY's PEG is ranked lower than
96% of the 95 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. RHHBY: 18.33 )
Ranked among companies with meaningful PEG only.
RHHBY' s PEG Range Over the Past 10 Years
Min: 0.24  Med: 1.23 Max: 23.21
Current: 18.33
0.24
23.21
Shiller P/E 20.41
RHHBY's Shiller P/E is ranked higher than
78% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. RHHBY: 20.41 )
Ranked among companies with meaningful Shiller P/E only.
RHHBY' s Shiller P/E Range Over the Past 10 Years
Min: 18.29  Med: 23.58 Max: 34.56
Current: 20.41
18.29
34.56
Current Ratio 1.09
RHHBY's Current Ratio is ranked lower than
87% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. RHHBY: 1.09 )
Ranked among companies with meaningful Current Ratio only.
RHHBY' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 1.85 Max: 3.75
Current: 1.09
1.09
3.75
Quick Ratio 0.75
RHHBY's Quick Ratio is ranked lower than
89% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. RHHBY: 0.75 )
Ranked among companies with meaningful Quick Ratio only.
RHHBY' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.5 Max: 3.22
Current: 0.75
0.75
3.22
Days Inventory 179.02
RHHBY's Days Inventory is ranked lower than
65% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. RHHBY: 179.02 )
Ranked among companies with meaningful Days Inventory only.
RHHBY' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 157.18 Max: 186.16
Current: 179.02
143.33
186.16
Days Sales Outstanding 64.10
RHHBY's Days Sales Outstanding is ranked lower than
52% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. RHHBY: 64.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.32  Med: 74.15 Max: 84.09
Current: 64.1
60.32
84.09
Days Payable 57.68
RHHBY's Days Payable is ranked higher than
50% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. RHHBY: 57.68 )
Ranked among companies with meaningful Days Payable only.
RHHBY' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 59.56 Max: 78.64
Current: 57.68
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.65
RHHBY's Dividend Yield is ranked higher than
87% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 1.46 vs. RHHBY: 3.65 )
Ranked among companies with meaningful Dividend Yield only.
RHHBY' s Dividend Yield Range Over the Past 10 Years
Min: 0.99  Med: 2.89 Max: 4.55
Current: 3.65
0.99
4.55
Dividend Payout 0.77
RHHBY's Dividend Payout is ranked lower than
87% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. RHHBY: 0.77 )
Ranked among companies with meaningful Dividend Payout only.
RHHBY' s Dividend Payout Range Over the Past 10 Years
Min: 0.61  Med: 1.09 Max: 1.38
Current: 0.77
0.61
1.38
Dividend Growth (3y) 5.60
RHHBY's Dividend Growth (3y) is ranked lower than
56% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. RHHBY: 5.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
RHHBY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 10.8 Max: 27.3
Current: 5.6
0
27.3
Forward Dividend Yield 3.76
RHHBY's Forward Dividend Yield is ranked higher than
88% of the 231 Companies
in the Global Biotechnology industry.

( Industry Median: 1.39 vs. RHHBY: 3.76 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.86
RHHBY's Yield on cost (5-Year) is ranked higher than
83% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 1.66 vs. RHHBY: 4.86 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RHHBY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.32  Med: 3.85 Max: 6.06
Current: 4.86
1.32
6.06
3-Year Average Share Buyback Ratio -0.10
RHHBY's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. RHHBY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHBY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -364.1  Med: 0 Max: 78.5
Current: -0.1
-364.1
78.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.53
RHHBY's Price/Projected FCF is ranked lower than
99.99% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. RHHBY: 1.53 )
Ranked among companies with meaningful Price/Projected FCF only.
RHHBY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0  Med: 1.73 Max: 6.63
Current: 1.53
0
6.63
Price/DCF (Earnings Based) 2.05
RHHBY's Price/DCF (Earnings Based) is ranked lower than
80% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. RHHBY: 2.05 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.97
RHHBY's Price/Median PS Value is ranked lower than
99.99% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. RHHBY: 0.97 )
Ranked among companies with meaningful Price/Median PS Value only.
RHHBY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0  Med: 1.05 Max: 1.29
Current: 0.97
0
1.29
Earnings Yield (Greenblatt) (%) 5.90
RHHBY's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. RHHBY: 5.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RHHBY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.5  Med: 7 Max: 13.1
Current: 5.9
4.5
13.1
Forward Rate of Return (Yacktman) (%) 7.29
RHHBY's Forward Rate of Return (Yacktman) (%) is ranked lower than
64% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.80 vs. RHHBY: 7.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RHHBY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.3  Med: 11.45 Max: 61.9
Current: 7.29
4.3
61.9

More Statistics

Revenue (TTM) (Mil) $52,759
EPS (TTM) $ 1.35
Beta0.65
Short Percentage of Float0.00%
52-Week Range $25.25 - 35.13
Shares Outstanding (Mil)6,817.65

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 51,497 55,486 63,171
EPS ($) 1.84 2.00 2.39
EPS w/o NRI ($) 1.84 2.00 2.39
EPS Growth Rate
(3Y to 5Y Estimate)
8.58%
Dividends Per Share ($) 1.03 1.10 1.16
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee Oct 14 2016 
Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
Innovative Diagnostic and Therapeutic Products Seen at Roche Aug 22 2016 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
Invesco Adds to Holdings in Investment, Financial Services Companies Jul 01 2016 
Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 

More From Other Websites
Biogen Underplays Promising Alzheimer's Data On Seizure Worries Dec 09 2016
5:41 am Roche Hldg receives EU approval for Venclyxto Dec 08 2016
Ariad Pharma Could Draw M&A Fire Ahead Of Second Cancer Drug Win Dec 07 2016
Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study Dec 07 2016
Sanofi May Battle Johnson & Johnson For European Biotech Actelion Dec 06 2016
Roche Presents Positive Follicular Lymphoma Data on Gazvya Dec 06 2016
Roche Group's Genentech says Avastin with chemo has been approved for specific advanced ovarian... Dec 06 2016
FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced... Dec 06 2016
Roche's Investors Remain Cautious Despite Improving Business Dec 06 2016
J&J Woos Billionaire Doctors Who Don’t Need Cash in Actelion Bid Dec 06 2016
Amgen/Allergan File for EU Approval of Avastin Biosimilar Dec 05 2016
Study raises questions over benefit of Roche's Gazyva cancer drug Dec 05 2016
Good Start Genetics Announces Marketing Agreement with Roche Diagnostics for Carrier Screening in... Dec 05 2016
Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly... Dec 04 2016
Merck KGaA (MKGAF) Expands Distribution Deal with Roche Dec 02 2016
Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study Dec 01 2016
Roche expands distribution alliance with the life science business of Merck KGaA, Darmstadt, Germany... Dec 01 2016
Pfizer's Herceptin biosimilar succeeds in key breast cancer study Nov 30 2016
Epizyme Tazemetostat Gets Fast Track Designation in U.S. Nov 29 2016
5 BioPharma Catalysts Expected Around Christmas Nov 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)